Bank of New York Mellon’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-11,973
| Closed | -$7K | – | 4341 |
|
|
2018
Q4 | $7K | Buy |
11,973
+51
| +0.4% | +$53 | ﹤0.01% | 4209 |
|
|
2018
Q3 | $15K | Sell |
11,922
-1
| -0% | -$2 | ﹤0.01% | 4221 |
|
|
2018
Q2 | $16K | Sell |
11,923
-55,967
| -82% | -$85.7K | ﹤0.01% | 4188 |
|
|
2018
Q1 | $98K | Sell |
67,890
-1,028
| -1% | -$2.15K | ﹤0.01% | 4064 |
|
|
2017
Q4 | $155K | Sell |
68,918
-607
| -0.9% | -$1.54K | ﹤0.01% | 3999 |
|
|
2017
Q3 | $237K | Sell |
69,525
-2,220
| -3% | -$7.47K | ﹤0.01% | 3823 |
|
|
2017
Q2 | $255K | Sell |
71,745
-6,869
| -9% | -$22.6K | ﹤0.01% | 3853 |
|
|
2017
Q1 | $267K | Buy |
78,614
+15,294
| +24% | +$59.5K | ﹤0.01% | 3789 |
|
|
2016
Q4 | $291K | Buy |
63,320
+1,727
| +3% | +$7.13K | ﹤0.01% | 3793 |
|
|
2016
Q3 | $261K | Buy |
61,593
+7,187
| +13% | +$23.2K | ﹤0.01% | 3814 |
|
|
2016
Q2 | $131K | Buy |
54,406
+19,469
| +56% | +$70.4K | ﹤0.01% | 4001 |
|
|
2016
Q1 | $164K | Buy |
34,937
+1,730
| +5% | +$6.7K | ﹤0.01% | 3847 |
|
|
2015
Q4 | $130K | Sell |
33,207
-23
| -0.1% | -$106 | ﹤0.01% | 3997 |
|
|
2015
Q3 | $129K | Buy |
33,230
+16,157
| +95% | +$74.2K | ﹤0.01% | 4040 |
|
|
2015
Q2 | $78K | Buy |
+17,073
| New | +$164K | ﹤0.01% | 4092 |
|
Bank of New York Mellon's AST Position: Q1 2019 in Review
Bank of New York Mellon sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 11,973 shares — an estimated $7K sold.
Bank of New York Mellon first reported a position in AST in Q2 2015 and held it in 15 quarters. The position peaked at $291K in Q4 2016. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Bank of New York Mellon reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Bank of New York Mellon sold 11,973 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $7K.
- Bank of New York Mellon first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 15 quarters.
- Bank of New York Mellon's Asterias Biotherapeutics Inc. Series A position peaked at $291K in Q4 2016.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Bank of New York Mellon's 13F filing for Q1 2019, filed 14 May 2019.